Cite
PDCT-09. PHASE 1/2 STUDY OF DSP-7888 IN PEDIATRIC PATIENTS WITH MALIGNANT GLIOMA
MLA
Keizo Horibe, et al. Pdct-09. Phase 1/2 Study of Dsp-7888 in Pediatric Patients with Malignant Glioma. Nov. 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....93e0f01142809dff67efdf9253e75bab&authtype=sso&custid=ns315887.
APA
Keizo Horibe, Junichi Hara, Keita Terashima, Saori Sugimoto, Takaaki Yanagisawa, Kazuhiko Sugiyama, Hiroyuki Fujisaki, Akinobu Watanabe, Hiroshi Kawamoto, Naoya Hashimoto, Hiroaki Goto, Yoshiko Hashii, & Atsushi Kikuta. (2018). Pdct-09. Phase 1/2 Study of Dsp-7888 in Pediatric Patients with Malignant Glioma.
Chicago
Keizo Horibe, Junichi Hara, Keita Terashima, Saori Sugimoto, Takaaki Yanagisawa, Kazuhiko Sugiyama, Hiroyuki Fujisaki, et al. 2018. “Pdct-09. Phase 1/2 Study of Dsp-7888 in Pediatric Patients with Malignant Glioma,” November. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....93e0f01142809dff67efdf9253e75bab&authtype=sso&custid=ns315887.